SAN FRANCISCO – Vir Biotechnology, Inc. (NASDAQ: NASDAQ: ) has shown encouraging results from a Phase 2 clinical trial, focusing on the treatment of chronic hepatitis B. The study evaluated the efficacy of tobevibart and elebsiran, with or without pegylated interferon alfa, and found significant levels of hepatitis B surface antigen (HBsAg) loss in participants with low HBsAg levels.
The trial involved two regimens: a doublet that included tobevibart and elebsiran, and a triplet that added pegylated interferon alfa. The doublet regimen resulted in 39% of participants with low baseline HBsAg achieving HBsAg loss, while the triplet regimen saw a 46% success rate. In addition, 50% of the doublet group and all in the triplet group who achieved HBsAg loss also experienced anti-HBs seroconversion, indicating a potential immune reaction to the virus.
The safety profile of the treatment remains consistent with previous studies, showing no new safety concerns and generally mild to moderate treatment-emergent adverse events.
The findings were presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® in San Diego on November 18, and further details will be discussed during an investor conference call on November 19.
The MARCH Phase 2 trial is part of a broader effort by Vir Biotechnology to develop a functional drug for chronic hepatitis B, which affects millions of people worldwide and can lead to serious liver complications. The company is patiently waiting for more data on functional medicine, anticipated in the second quarter of 2025, which will be important for the next stage of clinical development.
The report is based on a press statement from Vir Biotechnology, Inc.
In other recent news, Vir Biotechnology has reported significant developments during its third quarter 2024 earnings call. The company highlighted a license agreement with Sanofi (NASDAQ: ) for three T-cell engagement programs and advances in hepatitis trials. Vir’s R&D expenses increased by $195 million due to this transaction, but SG&A expenses decreased to $25.7 million. The company ended the quarter with $1.19 billion in cash and similarly, updated its full-year 2024 expense guidance to between $660 million and $680 million.
The company is making progress with its hepatitis program and plans to start a registration program for hepatitis delta virus (HDV) in 2025. The Vir T cell engagement program is progressing, with Phase I trials ongoing and initial data expected in Q1 2025. More than 50% of patients in the SOLSTICE study achieved an “undetectable” viral load at week 24.
New CFO Jason O’Byrne emphasized disciplined financial management in line with strategic restructuring. Vir expects to share details of the registration program at the post-AASLD hepatitis focused investor event. The company targets approximately 100,000 HDV patients in the US and aims to improve early diagnosis and achieve a functional cure in chronic hepatitis B. This is a new development for Vir Biotechnology.
InvestingPro Insights
Vir Biotechnology’s promising clinical trial results come at an important time for the company, as reflected in recent financial data and analyst perspectives. According to InvestingPro, Vir’s market capitalization is $1.11 billion, indicating a significant presence in the biotech sector despite recent challenges.
InvestingPro Tips reveals that Vir has more cash than debt on its balance sheet, which is very important for a biotech company that invests heavily in research and development. This financial stability could provide the runway necessary for Vir to continue clinical trials and potentially bring hepatitis B treatments to market.
However, the company is currently facing several problems. InvestingPro Tips notes that Vir is rapidly burning through cash, which is unusual for a development-stage biotech company but requires careful management. Additionally, the stock has taken a big hit over the past week, with a 1-week total price of -10.0%, possibly reflecting market volatility or investor concern.
On the revenue front, Vir reported $78.62 million over the past twelve months, with revenue growth of -33.82% over the same period. This is in line with other InvestingPro Tips indicating that analysts expect sales to decline this year. However, it should be noted that biotech companies often experience revenue fluctuations during the transition from research to the commercialization phase.
Despite these challenges, there are positive signals. Four analysts have revised earnings upward for the upcoming period, indicating optimism about Vir’s future performance. In addition, the company’s price-to-book ratio of 0.9 indicates that the stock may be undervalued relative to its assets, which may attract investors who see the company’s long-term potential.
For those interested in a more in-depth analysis, InvestingPro offers additional tips and insights that may be useful in evaluating Vir Biotechnology’s investment potential. There are 11 other InvestingPro Tips available for VIR, providing a comprehensive view of the company’s financial health and market position.
This article was created with the support of AI and was reviewed by the editor. For more information see our T&C.
